MARKSANS PHARMA LTD.
Smart Quotes
Trade Value (Rs. in Lacs) | 0.00 |
Dividend Yield(%) | 0.33 |
TTM EPS (Rs.) | 2.62 |
P/E Ratio | 57.92 |
Book Value (Rs.) | 26.24 |
Face Value (Rs.) | 1 |
MCap (Rs. in Mn) | 68676.97 |
Price/Earning (TTM) | 47.78 |
Price/Sales (TTM) | 8.79 |
Price/Book (MRQ) | 5.78 |
PAT Margin (%) | 14.79 |
ROCE (%) | 14.27 |
Management Info :
Mark Saldanha - Chairman Mark Saldanha - Managing DirectorRegistered Office :
Address :
11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (W),
Mumbai,
Maharashtra-400053
Phone : 022- 40012000
Website : www.marksanspharma.com
QTR Dec 23 | ANNUAL 23 | |
---|---|---|
Net Profit | 252.87 | 1028.66 |
Gross Profit | 345.99 | 1320.35 |
Operating Profit | 433 | 1523.85 |
Net Sales | 2413.64 | 6552.04 |
Abbott India (BSE)  26946.00 (0.74%) | M.Cap ( in Cr) 57258.37 |
Sanofi India (BSE)  8118.25 (2.06%) | M.Cap ( in Cr) 18696.83 |
Dr. Reddy's Lab (BSE)  6155.15 (1.78%) | M.Cap ( in Cr) 102679.14 |
Divi's Lab (BSE)  3436.75 (2.14%) | M.Cap ( in Cr) 91234.91 |
Glaxosmithkline Phar (BSE)  1943.10 (3.26%) | M.Cap ( in Cr) 32917.29 |
|
PROMOTERS | 43.85 % |
|
NON-INSTITUTION | 35.83 % |
|
MUTUAL FUNDS/UTI | 3.82 % |
|
FI/BANKS/INSURANCE | 0 % |
|
GOVERNMENT | 0 % |
|
FII | 0 % |
Scheme Name | Hold(%) |
---|---|
Quant Small Cap Fund(G) | 1.57 |
UTI Large & Mid Cap Fun... | 0.73 |
UTI Aggressive Hybrid F... | 0.64 |
Motilal Oswal Nifty Mic... | 0.59 |
Motilal Oswal S&P BSE H... | 0.46 |
UTI Healthcare Fund-Reg... | 0.43 |